Gabapentin News and Research RSS Feed - Gabapentin News and Research

Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Anticonvulsant medication gabapentin effectively reduces common complication of PONV

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

The anticonvulsant medication gabapentin—already a useful part of strategies to control pain after surgery—also effectively reduces the common complication of postoperative nausea and vomiting (PONV), reports a study in Anesthesia & Analgesia. [More]
Breckenridge Pharmaceutical announces final FDA approval for Gabapentin Oral Solution

Breckenridge Pharmaceutical announces final FDA approval for Gabapentin Oral Solution

Breckenridge Pharmaceutical, Inc. announces the final approval by the U.S. Food and Drug Administration of the Abbreviated New Drug Application for Gabapentin Oral Solution 250 mg per 5 mL, which is AA rated to Neurontin, a drug marketed by Pfizer. [More]
American Pain Society releases new post-surgical pain management guideline

American Pain Society releases new post-surgical pain management guideline

The American Pain Society has released a new evidence-based clinical practice guideline, appearing in The Journal of Pain, with 32 recommendations to help clinicians achieve optimal pain management following surgery. According to numerous studies, the majority of surgical patients receive inadequate pain relief, which can heighten the risk for prolonged post-surgical pain, mood disorders and physical impairment. [More]
Noninvasive FMRI may help evaluate effectiveness of new pain medications

Noninvasive FMRI may help evaluate effectiveness of new pain medications

New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies. [More]
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual. [More]
NAMS panel provides recommendations to help women manage menopause-associated vasomotor symptoms

NAMS panel provides recommendations to help women manage menopause-associated vasomotor symptoms

Some three-quarters of North American women have menopausal hot flashes, but many cannot use hormones for medical reasons or choose not to. Numerous products and techniques are promoted for hot flashes, but do they work, and are they safe? To answer these questions, a North American Menopause Society panel of experts weighed the evidence and made recommendations in a position statement, "Nonhormonal management of menopause-associated vasomotor symptoms," published online today in the Society's journal, Menopause. [More]
Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture may be viable treatment for women experiencing hot flashes

Acupuncture may be a viable treatment for women experiencing hot flashes as a result of estrogen-targeting therapies to treat breast cancer, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania. Hot flashes are particularly severe and frequent in breast cancer survivors, but current FDA-approved remedies for these unpleasant episodes, such as hormone replacement therapies are off-limits to breast cancer survivors because they include estrogen. [More]
Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

Acupuncture: A viable treatment for breast cancer survivors experiencing hot flashes

Acupuncture may be a viable treatment for women experiencing hot flashes as a result of estrogen-targeting therapies to treat breast cancer, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania. Hot flashes are particularly severe and frequent in breast cancer survivors, but current FDA-approved remedies for these unpleasant episodes, such as hormone replacement therapies are off-limits to breast cancer survivors because they include estrogen. [More]
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). [More]
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. [More]
Researchers investigate effects of neuromodulatory medication on orofacial tissue

Researchers investigate effects of neuromodulatory medication on orofacial tissue

Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher M.J. Al-Musawi, Newcastle University, Newcastle upon Tyne, UK, will present a study titled "In Vitro Effects of Topical Neuromodulatory Medication on Orofacial Tissue." [More]
Unmet medication need in neuropathic pain

Unmet medication need in neuropathic pain

A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients. [More]
Perampanel does not offer added benefit for patients with Epilepsy

Perampanel does not offer added benefit for patients with Epilepsy

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). [More]
XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis. [More]
Study determines effectiveness of gabapentin for treatment of vulvodynia in women

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

A chronic syndrome called vulvodynia that affects from four to seven percent of women is being studied by physicians at The Women's Health Institute at Robert Wood Johnson Medical School, part of Rutgers, The State University of New Jersey, in hopes of alleviating sometimes excruciating pain. [More]
XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million. [More]
FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

A report in the Feb. 13 New England Journal of Medicine confirms previous studies suggesting that long-term treatment with the type of drugs commonly prescribed to treat restless leg syndrome (RLS) can cause a serious worsening of the condition in some patients. [More]
Study sheds light on the biological underpinnings of obesity

Study sheds light on the biological underpinnings of obesity

A new neuroscience study sheds light on the biological underpinnings of obesity. The in vivo study, published in the January 8 issue of the Journal of Neuroscience, reveals how a protein in the brain helps regulate food intake and body weight. The findings reveal a potential new avenue for the treatment of obesity and may help explain why medications that are prescribed for epilepsy and other conditions that interfere with this protein, such as gabapentin and pregabalin, can cause weight gain. [More]
Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties - an effect for which these pharmaceutical agents are not usually tested. [More]
Depomed reports financial results for third quarter 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012. [More]
Advertisement
Advertisement